摘要
目的分析新型冠状病毒肺炎(COVID-19)住院患者阿兹夫定片的使用合理性及不良事件发生情况,为临床合理用药提供参考。方法采用回顾性研究方法,对襄阳市中心医院2022年11月1日—2022年12月31日因COVID-19住院且使用阿兹夫定片的患者进行全样本点评,从药物适应证、用法用量、给药时机、用药疗程、联合用药等方面评价用药合理性,同时考察用药后不良事件发生率,评估用药安全性。结果使用阿兹夫定片的患者共计284例,其中122例用药不合理,不合理率42.96%。不合理用药共发生179例次,适应证不适宜74例次(26.06%),用法用量不适宜70例次(24.65%),联合用药不适宜24例次(8.45%)。使用阿兹夫定片患者中77例(27.11%)在用药后共发生151项不良事件,其中血小板计数改变、乳酸升高、总胆汁酸升高及胃肠不适最常见。点评结果为“不合理”的病例不良事件发生率(35.25%)显著高于点评结果为“合理”的病例(20.99%)。结论阿兹夫定片临床用药存在不合理情况,且不合理用药与患者住院期间不良事件的发生密切相关,临床应用时应加强监管和干预,促进临床合理用药,保障患者用药安全。
Objective To analyze the clinical application rationality and adverse reactions of Azvudine Tablets in hospitalized patients with COVID-19 and to provide references for the rational drug use.Methods Data of the cases using Azvudine Tablets in Xiangyang Central Hospital from November 1,2022 to December 31,2022 were retrospectively collected and analyzed,in terms of indication,dosage and usage,medication timing,medication course,and combination of drugs.At the same time,the incidence of adverse reactions after drug use were investigated,in order to evaluate medication safety.Results There were a total of 284 cases using Azvudine Tablets among which 122 cases used unreasonably,with an unreasonable rate of 42.96%.There were totally 179 cases of unreasonable use of Azvudine Tablets including 74 cases(26.06%)of inappropriate indications,70 cases(24.65%)of improper usage and dosage,and 24 cases(8.45%)of improper combination.A total of 151 adverse reactions occurred after Azvudine Tablets treatment for 77 patients(27.11%),of which platelet count change,lactic acid increase,total bile acid increase and gastrointestinal discomfort were the most common.And the incidence of adverse reactions(35.25%)of cases with"unreasonable"results was significantly higher than that with"reasonable"results(20.99%).Conclusion There were unreasonable use of Azvudine Tablets in clinic,which were closely related to the occurrence of adverse reactions,and need to be intervened in order to promote rational drug use and ensure drug safety of patients.
作者
陈龙
刘明佳
罗旋
刘恩泽
丁楠楠
CHEN Long;LIU Mingjia;LUO Xuan;LIU Enze;DING Nannan(Department of Pharmacy,Xiangyang Central Hospital,Affiliated Hospital of Hubei University of Arts and Sciences,Xiangyang 441021,China;Department of Blood Transfusion,Xiangyang Central Hospital,Affiliated Hospital of Hubei University of Arts and Sciences,Xiangyang 441021,China;Department of Pharmacy,Yicheng People's Hospital,Yicheng 441400,China)
出处
《药物评价研究》
CAS
2023年第10期2201-2207,共7页
Drug Evaluation Research
基金
湖北省卫健委2018—2019年中医药科研项目(青年人才项目)(ZY2019Q013)
襄阳市2021年度医疗卫生领域科技计划项目(2021ZD05)。
